Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Amortization of Goodwill (2024 - 2025)

Maravai Lifesciences Holdings (MRVI) has 2 years of Amortization of Goodwill data on record, last reported at $30.4 million in Q2 2025.

  • For Q2 2025, Amortization of Goodwill changed N/A year-over-year to $30.4 million; the TTM value through Sep 2025 reached $209.0 million, up 35.5%, while the annual FY2024 figure was $166.2 million, N/A changed from the prior year.
  • Amortization of Goodwill reached $30.4 million in Q2 2025 per MRVI's latest filing, up from $12.4 million in the prior quarter.
  • Across five years, Amortization of Goodwill topped out at $166.2 million in Q4 2024 and bottomed at $12.4 million in Q1 2025.